Alkermes - 30 Year Stock Price History | ALKS

Historical daily share price chart and data for Alkermes since 1991 adjusted for splits. The latest closing stock price for Alkermes as of September 24, 2021 is 32.08.
  • The all-time high Alkermes stock closing price was 98.05 on March 01, 2000.
  • The Alkermes 52-week high stock price is 32.52, which is 1.4% above the current share price.
  • The Alkermes 52-week low stock price is 15.35, which is 52.2% below the current share price.
  • The average Alkermes stock price for the last 52 weeks is 22.12.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Alkermes Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 23.5438 19.7400 32.0800 18.2100 32.0800 60.80%
2020 17.6377 19.7600 22.1000 13.0600 19.9500 -2.21%
2019 25.4200 29.1100 37.3300 17.2900 20.4000 -30.87%
2018 45.9911 55.2200 67.2600 27.9400 29.5100 -46.08%
2017 54.8201 56.1000 61.6600 47.6900 54.7300 -1.53%
2016 45.4797 74.8300 75.2700 29.0500 55.5800 -29.98%
2015 66.3880 58.2400 80.1400 55.0800 79.3800 35.55%
2014 47.3686 40.2400 58.8800 40.0700 58.5600 44.02%
2013 30.2678 19.2800 41.1200 19.2800 40.6600 119.55%
2012 18.1842 17.3400 20.8800 15.1200 18.5200 6.68%
2011 15.4301 12.5500 19.5200 12.1400 17.3600 41.37%
2010 12.4457 9.7100 15.9200 9.6900 12.2800 30.50%
2009 9.6079 10.7100 13.1300 7.5600 9.4100 -11.64%
2008 12.2140 15.1000 16.8900 6.1000 10.6500 -31.69%
2007 15.7875 13.0900 18.5600 12.7600 15.5900 16.60%
2006 18.9792 20.5200 26.7100 13.1800 13.3700 -30.07%
2005 14.4015 14.0100 19.6600 10.0100 19.1200 35.70%
2004 13.3925 13.9700 16.8600 8.5100 14.0900 4.37%
2003 11.0874 6.6600 15.5600 6.5200 13.5000 115.31%
2002 15.1033 25.7500 30.3400 3.7800 6.2700 -76.21%
2001 26.8799 27.6300 37.1000 17.5000 26.3600 -16.00%
2000 41.5542 25.5000 98.0500 23.6250 31.3800 27.74%
1999 15.7511 11.6900 26.8150 11.4400 24.5650 121.41%
1998 9.9991 9.9400 13.3750 5.3150 11.0950 11.62%
1997 9.5169 11.1900 14.6900 5.1900 9.9400 -14.49%
1996 6.2174 3.7500 12.1250 3.7500 11.6250 192.89%
1995 2.4000 1.0315 4.3125 1.0000 3.9690 273.55%
1994 2.4714 3.6875 4.5000 1.0625 1.0625 -69.64%
1993 4.1401 4.5000 5.5000 3.1250 3.5000 -17.65%
1992 6.0673 9.0000 14.1900 2.7500 4.2500 -52.78%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.148B $1.039B
Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71